Sarepta therapeutics announces progress on the myoaav program and exclusive licensing agreement with the broad institute for myoaav next-generation capsids for rare genetic diseases

Following internal corroboration of published results on the myoaav platform, sarepta secures exclusive license for duchenne muscular dystrophy, plus four additional neuromuscular and cardiac indications
SRPT Ratings Summary
SRPT Quant Ranking